T1	Participants 236 296	patients with stage I-III non-small cell lung cancer (NSCLC)
T2	Participants 743 895	Patients were eligible if they had stage I-IIIB NSCLC, unsuitable for curative therapy, or stage IV with a PET-detected extracranial solitary metastasis
T3	Participants 1290 1326	Eighty-four patients were randomized
